## axinn

# Federal Circuit Rules for Axinn Client in Abilify Patent Appeal

NEWS | 1 MIN READ

July 20, 2017

In Axinn's latest for win for its client Zydus in assisting their coming to market with their generic version of Abilify (aripiprazole), the Federal Circuit affirmed a district court's claim construction in ongoing litigation between Otsuka and Zydus concerning Abilify® (aripiprazole). The appeal concerned the construction of U.S. Patent No. 8,759,350, which the district court had construed favorably for Zydus. After obtaining a stipulated summary judgment of non-infringement concerning the '350 patent based on this construction, Otsuka appealed to the Federal Circuit. The panel held a hearing in July and subsequently rejected Otsuka's argument, affirming the district court in a unanimous decision.

Click here to read Law360's review of the win. A subscription is required.

#### **Related People**



Jason Murata

#### **Related Services**

Intellectual Property

To subscribe to our publications, click here.

### **Featured Insights**

- American Bar Association 2025 Asia-Pacific Conference
  SPEAKING ENGAGEMENT ANTITRUST
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference
  sponsorship ANTITRUST
- GCR Live: Law Leaders Global 2025
  SPEAKING ENGAGEMENT ANTITRUST
- The 32nd Annual Marketing Partner Forum
  EVENT
- SABA North America Corporate Counsel Retreat 2025
  sponsorship ANTITRUST
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025
  **CLIENT ALERTS ANTITRUST**
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards
  AWARDS & RECOGNITIONS ANTITRUST
- Merger Remedies Back in Vogue Under Trump
  MEDIA MENTIONS ANTITRUST
- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation
   AXINN VIEWPOINTS INTELLECTUAL PROPERTY

• A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness

AXINN VIEWPOINTS INTELLECTUAL PROPERTY

@ 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved